Skip to main content

RegMedNet is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Topics
    • CAR-T
      • Stem cells
      • Cell therapy
      • Gene therapy
      • Gene editing
    • Cancer
      • Preclinical research
      • Tissue engineering
      • 3D printing
      • Biobanking
    • Clinical trials & funding
      • Manufacturing & scale-up
      • Regulation & policy
      • Industry developments

    Follow us on social media

  • Explore content
    • News
      • The week in cell therapy
      • Spotlights
      • In Focus
      • Interviews
      • Opinion
      • Report
      • App Notes & White Papers
    • eBooks
      • Webinars
      • Podcasts
      • Videos
      • Infographics
      • Partners
      • Events
      • Events news
      • Glossary

    Follow us on social media

  • Our journals
    • Our journals
    • Journal content
    • Journal articles

    Follow us on social media

  • Register
From research to clinical production: scaling iPSC and extracellular vesicle processes 11 days 9 hours 54 mins 16 secs REGISTER NOW

iPSCs: take the survey and win!

7 Jan 2025
Cell therapy Gene therapy iPSCs News Stem cells

As part of our Spotlight feature on induced pluripotent stem cells (iPSCs), we’re inviting you to share your insights on the use of iPSCs in cell and gene therapy and regenerative medicine. Your valuable input will help shape our understanding of current trends and challenges in this exciting area of research and development.

This survey is now closed.

This survey is part of the RegMedNet Spotlight on iPSCs. Click here to view the full feature and discover expert insights on this >>>

Top content

  • Phase I/II Parkinson’s disease cell therapy trial achieves primary endpoint
  • Cell therapy weekly: investigational AAV-based gene therapy for FSHD completes enrollment
  • Novel gene therapy harnesses brain’s glymphatic system for targeted delivery

Related tags

iPSCs Survey
Previous article Next article

Related articles

2 MAY 2024 IPSCS
Inhale, exhale, in vitro: generating epithelial iPSCs
7 JAN 2025 IPSCS
GMP compliant iPSC lines and immune-oncology platform for allogeneic cell therapy
19 JUN 2025 APP NOTES & WHITE PAPERS
Solutions for the culturing, maintaining and characterization of induced pluripotent stem cells
23 APR 2020 3D PRINTING
3D-printed device could facilitate point-of-care drug combination testing
16 SEP 2020 NEWS
First stem cells discovered to produce placenta cells
28 JAN 2025 IPSCS
Minimizing variability and maximizing quality in iPSC cultures: an interview with Nathan Frank
  • About
  • Advertising & Sponsorship
  • Expert Panel
  • Permissions & content ownership policy
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

RegMedNet is powered by Taylor & Francis Group

RegMedNet, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 RegMedNet